EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management

Karel David iD, Paul Van Crombrugge, Anne-Marie Van der Biest, Frederiek D'Hondt, Frank Claessens, Alexander Giesen, Steven Joniau, Brigitte Decallonne iD

European Thyroid Journal · 17.09.2024 · 13 (5)

DOI: 10.1530/etj-24-0158 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Thyroid Journal, erschienen am 17.09.2024. Verfasst von Karel David und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Hypothyroidism, Thiohydantoins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The androgen receptor signaling inhibitor apalutamide is used successfully for the treatment of prostate cancer. An increased risk of hypothyroidism, mostly subclinical, has been reported in the SPARTAN and TITAN trials. We present three cases of subacute deterioration of previously known but well-controlled hypothyroidism treated with levothyroxine, occurring shortly after the initiation of treatment with apalutamide, resulting in severe hypothyroidism. These cases highlight the importance of awareness of thyroid dysfunction during treatment with apalutamide, particularly in patients with pre-existing thyroid disease, common in the general population. We provide practice recommendations for thyroid management prior to and during apalutamide treatment as well as after the interruption of this therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypothyroidismThiohydantoinsHumansMaleAgedThyroxineMiddle AgedProstatic NeoplasmsPractice Guidelines as TopicAged, 80 and over

Stichwörter der Autor:innen

apalutamideglucuronidationhypothyroidismlevothyroxineprostate cancer

Substanzen

ThiohydantoinsapalutamideThyroxine

Autor:innen und Institutionen

  • Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Endocrinology, OLV Hospital, Aalst, Belgium.
  • Department of Endocrinology, AZ Glorieux, Ronse, Belgium.
  • Department of Urology, OLV Hospital, Aalst, Belgium.
  • Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Department of Urology, University Hospitals Leuven, Leuven, Belgium.

ORCID-Profile: Karel David, Brigitte Decallonne

Zitieren

APA

David, K., Van Crombrugge, P., Van der Biest, A. M., D'Hondt, F., Claessens, F., Giesen, A., Joniau, S., & Decallonne, B. (2024). Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. European Thyroid Journal, 13(5). https://doi.org/10.1530/etj-24-0158

Vancouver

David K, Van Crombrugge P, Van der Biest AM, D'Hondt F, Claessens F, Giesen A, et al. Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. European Thyroid Journal. 2024;13(5). doi:10.1530/etj-24-0158

BibTeX
@article{David2024,
  author = {David, Karel and Van Crombrugge, Paul and Van der Biest, Anne-Marie and D'Hondt, Frederiek and Claessens, Frank and Giesen, Alexander and Joniau, Steven and Decallonne, Brigitte},
  title = {Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management},
  journal = {European Thyroid Journal},
  year = {2024},
  volume = {13},
  number = {5},
  doi = {10.1530/etj-24-0158}
}
Kostenlos starten →